Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luprodex vs Lucrin in Advanced Prostate Cancer
NCT04914195Phase 3Completed
- Sponsor
- Bharat Serums and Vaccines
- Start
- Jul 2021
- Primary completion
- Sep 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Luprodex in prostate adenocarcinoma (2 arms), sponsored by Bharat Serums and Vaccines. Primary endpoint: Testosterone response rate. Started Jul 2021; status: completed.
02
Drugs
Luprodex
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT04914195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04914195.